5-Amino-1MQ 50mg

Quickstart Highlights

5-Amino-1MQ dosage protocols center on this selective, cell-permeable NNMT (Nicotinamide N-methyltransferase) inhibitor studied for its potential to support fat metabolism, preserve lean muscle mass, and elevate intracellular NAD+ levels[1][2]. By blocking NNMT, 5-Amino-1MQ may help restore cellular energy balance and activate SIRT1 pathways associated with metabolic efficiency[3]. This educational protocol presents a subcutaneous injection approach to maximize bioavailability from the 50 mg vial format.

Reconstitute: Add 4.0 mL bacteriostatic water → 12.5 mg/mL concentration.
Typical daily range: 2.5–5 mg once or twice daily (subcutaneous).
Easy measuring: At 12.5 mg/mL, 1 unit = 0.01 mL = 0.125 mg (125 mcg) on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 2–4 weeks.

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Subcutaneous Protocol (4 mL = 12.5 mg/mL)

Phase	Daily Dose (mg)	Units (per injection) (mL)
Days 1–2 (Tolerance)	2.5 mg once daily	20 units (0.20 mL)
Days 3+ (Standard)	5 mg once daily	40 units (0.40 mL)
Alternative BID	2.5 mg twice daily	20 units (0.20 mL) × 2

Frequency: Inject once or twice daily subcutaneously. Due to the compound’s plasma half-life of approximately 3.8–6.9 hours[4], twice-daily (BID) dosing may provide more sustained NNMT inhibition. A single 50 mg vial provides 10–20 days of research material at these doses.

Reconstitution Steps

Reference-derived details for 5-Amino-1MQ 50mg.

Remove the vial from freezer storage (−20 °C / −4 °F) and allow to equilibrate at room temperature for 15–20 minutes.
Draw 4.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved—solution should be clear (do not shake).
Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 2–4 weeks.

Supplies Needed

Plan based on research duration using the 50 mg vial format at 5 mg/day.

5-Amino-1MQ Vials (50 mg each):
5-Amino-1MQ Vials (50 mg each):: 1 week (5 mg/day) ≈ 1 vial
5-Amino-1MQ Vials (50 mg each):: 2 weeks (5 mg/day) ≈ 1 vial
5-Amino-1MQ Vials (50 mg each):: 4 weeks (5 mg/day) ≈ 2 vials
Insulin Syringes (U-100):
Insulin Syringes (U-100):: Per week (once daily): 7 syringes
Insulin Syringes (U-100):: Per week (BID): 14 syringes
Insulin Syringes (U-100):: 4 weeks (once daily): 28 syringes
Bacteriostatic Water (10 mL bottles): Use 4.0 mL per vial for reconstitution.
Bacteriostatic Water (10 mL bottles): Use 4.0 mL per vial for reconstitution.: 1 week (1 vial): 4 mL → 1 × 10 mL bottle
Bacteriostatic Water (10 mL bottles): Use 4.0 mL per vial for reconstitution.: 2 weeks (1 vial): 4 mL → 1 × 10 mL bottle
Bacteriostatic Water (10 mL bottles): Use 4.0 mL per vial for reconstitution.: 4 weeks (2 vials): 8 mL → 1 × 10 mL bottle
Alcohol Swabs: One for the vial stopper + one for the injection site each administration.
Alcohol Swabs: One for the vial stopper + one for the injection site each administration.: Per week (once daily): 14 swabs
Alcohol Swabs: One for the vial stopper + one for the injection site each administration.: 4 weeks (once daily): 56 swabs → recommend 1 × 100-count box

Protocol Overview

Concise summary of the subcutaneous regimen.

Goal: Support metabolic efficiency through NNMT inhibition, potentially enhancing fat oxidation and NAD+ levels[1][2]. Open source
Schedule: Daily subcutaneous injections; each 50 mg vial provides 10–20 days of research material.
Dose Range: 2.5–5 mg once or twice daily.
Reconstitution: 4.0 mL per 50 mg vial (12.5 mg/mL) for accurate measurements.
Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F).

Dosing Protocol

Suggested approach for the 50 mg vial format.

Start: 2.5 mg once daily to assess tolerance.
Target: 5 mg once daily or 2.5 mg twice daily (BID).
Frequency: Once or twice per day (subcutaneous).
Vial Duration: Single 50 mg vial lasts 10–20 days at research doses.
Timing: Morning administration preferred; BID dosing may be split AM/PM.

Storage Instructions

Proper storage preserves compound stability.

Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; stable up to 24 months.
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 2–4 weeks.
Allow vials to reach room temperature before reconstitution to prevent condensation and pressure issues.
Do not refreeze reconstituted solution.

Important Notes

Practical considerations for consistency and safety.

Use new sterile insulin syringes for each administration; dispose in a sharps container.
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
Inject slowly; a mild stinging sensation may occur due to the quinolinium structure.
Document daily dose and site rotation to maintain consistency.
The 50 mg vial format is ideal for extended research cycles; a single vial can last 10–20 days.

How This Works

5-Amino-1MQ (5-amino-1-methylquinolinium) is a synthetic small molecule that selectively inhibits Nicotinamide N-methyltransferase (NNMT)[1]. NNMT is an enzyme that methylates nicotinamide (vitamin B3) using S-adenosylmethionine (SAM) as a methyl donor. In states of obesity and metabolic dysfunction, NNMT is often overexpressed in adipose tissue, depleting nicotinamide and reducing NAD+ availability[2].

By inhibiting NNMT, 5-Amino-1MQ may spare nicotinamide for NAD+ synthesis, thereby activating SIRT1 (Sirtuin 1) pathways associated with mitochondrial biogenesis and fat oxidation[3]. Preclinical studies indicate that NNMT knockdown or inhibition can protect against diet-induced weight gain and improve metabolic parameters without reducing food intake[5][6].

Potential Benefits & Side Effects

Observations from preclinical and early research literature.

May support reductions in fat mass while preserving lean muscle in animal models[5][6]. Open source
Associated with elevated NAD+ levels and SIRT1 activation in preclinical studies[2][3]. Open source
Enhanced grip strength observed in aged mice when combined with exercise[7]. Open source
Generally well tolerated; occasional reports of mild headache, transient jitteriness, or injection-site reactions.
Long-term human safety data not established; this compound remains investigational.

Injection Technique

General subcutaneous guidance from clinical best-practice resources[9].

Clean the vial stopper and skin with alcohol; allow to dry.
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[10][11]. Open source
Do not aspirate for subcutaneous injections; inject slowly and steadily[10]. Open source
Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[12]. Open source
Slow injection may minimize any stinging sensation associated with the compound.

Lifestyle Factors

Complementary strategies for best outcomes.

Pair with a balanced, protein-forward diet tailored to energy needs.
Combine resistance training and aerobic activity—preclinical data suggest synergy with exercise[7]. Open source
Prioritize sleep and stress management to support metabolic adaptation.
Consider complementary NAD+ precursors (NMN/NR) per emerging stack protocols[8]. Open source

Recommended Source

We recommend Prime Lab Peptides for high-purity 5-Amino-1MQ (50 mg).

High-purity (≥99% HPLC), third-party-tested lots with batch COAs.
Consistent, ISO-aligned handling and documentation.
Reliable fulfillment to maintain cold-chain integrity.

Important Note

This page is informational and does not authorize use. Peptify clients should complete assessment, disclose medications and health history, and follow the clinician-approved plan only.

Do not start, stop, combine, or change a protocol based only on website content.
Emergency symptoms require urgent medical care, not a website or routine follow-up message.

References